Current report No. 8/2012
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from January 19 2012 up to and including January 25 2012 the Company bought 500 own shares representing 0.00038% of the share capital of the Company, to the total value of BGN 1450 on the Bulgarian Stock Exchange. The average price per share was 2.90 BGN.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
Sopharma issued its Q4 2011 Individual Financial Report. It is published in the Financial Information Section -> Reports.
We would like to notify that for the month of January 2012 due to the bad weather conditions Sopharma AD realized decrease in sales revenues on annual basis of 17%, including 37% for the domestic market, 9% for the export markets.
In an article dated February 4, 2012 under the name “Sopharma of Bulgaria under EU investigation” the issue of New Europe claims that Sopharma is under investigation by the EU institution (name and function is not specified) onsite in Bulgaria in relation to managing to “to supply more than 70% of the medicines required by (state) hospitals and more than 50% of prescribed medicines”. We would like to draw attention to the fact that the claim of such investigation is completely unjustified and is not supported by any evidence.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from February 23 2012 up to and including February 29 2012 the Company bought 298 own shares representing 0.000226% of the share capital of the Company, to the total value of BGN 822.67 on the Bulgarian Stock Exchange. The average price per share was 2.76 BGN.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
We would like to notify that for the month of February, 2012 Sopharma AD realized growth of sales revenues of 20% compared with the same month of the previous year, including 10% decrease of domestic sales 33% growth of export sales.
From the beginning of this year sales revenues increased with 3%, including 23% decrease of domestic sales and 13 % growth of export sales.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 01 March 2012 up to and including 07 March 2012 the Company bought 200 own shares representing 0.00015% of the share capital of the Company, to the total value of 570 BGN on the Bulgarian Stock Exchange. The average price per share was 2.85 BGN.
The shares have been bought on the basis of the general meeting resolution of 23.06.2010.
The intention of the Company is to use the repurchased shares in the future for the purpose of providing them to shareholders of companies targeted in mergers.
We would like to notify that for the month of March, 2012 Sopharma AD realized decrease of sales revenues of 14% compared with the same month of the previous year, including 10% decrease of domestic sales and 16% decrease of export sales.
During the last two months we managed to compensate the decrease from January, caused by force major conditions and we finish the first quarter of 2012 with 3% decrease of sales revenues compared with the same quarter of 2011, including 18% decrease of domestic sales and 3% increase of export sales.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 5 April 2012 up to and including 11 April 2012 the Company bought 500900 own shares representing 0.379% of the share capital of the Company, to the total value of BGN 1137354 on the Bulgarian Stock Exchange. The average price per share was BGN 2.27.
The shares have been bought on the basis of the general meeting resolution of 23.06.2010.
The Board of Directors of Sopharma AD (the “Company”) announces that it took a decision to sell 8976 ordinary registered shares with voting rights, representing 51% of the capital of ZAO "Rostbalkanpharm", city of Azov, Rostov region, Russian Federation, divided into 17,600 common shares of emission with state registration № 1-01-58454-P.
